Amethyst Radiotherapy Group Expands with €300m Financing Agreement
Amethyst Radiotherapy Group, a Pan European oncology company, recently announced a significant financing agreement of €300m with Credit funds managed by Ares Management Corporation, a global alternative investment manager. This partnership solidifies Amethyst's position as a key player in the European oncology sector and sets the stage for further expansion. The company's primary goal is to provide innovative cancer care to more patients, meeting the growing demand for accessible and high-quality oncological services.
Under the leadership of CEO Stéphane Carré, Amethyst Radiotherapy Group operates as a private operator of radiotherapy services, delivering cutting-edge cancer treatment across Europe.
With a strong emphasis on advanced technology and patient-centered care, the company is committed to enhancing health outcomes for cancer patients and creating a supportive environment for healthcare professionals. Currently, Amethyst has a presence in six countries, operating 15 state-of-the-art treatment centers.
Notably, Amethyst Radiotherapy Group has centers in key European cities including Vienna, Paris, Rome, Warsaw, Bucharest, and London. By strategically expanding its footprint across these regions, Amethyst aims to reach more patients in need of advanced cancer care and to set new standards in the oncology field. This recent financing agreement with Ares Management Corporation will enable the company to further its mission of improving cancer treatment outcomes and delivering top-quality healthcare services across Europe.
They've invested in Amethyst Radiotherapy
Get to know these Healthtech investors
Click here for a full list of 6,528+ startup investors in the UK